Revolution Medicines (NASDAQ:RVMD) CFO Jack Anders Sells 10,000 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $98.00, for a total transaction of $980,000.00. Following the sale, the chief financial officer directly owned 108,065 shares of the company’s stock, valued at approximately $10,590,370. This trade represents a 8.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Jack Anders also recently made the following trade(s):

• On Tuesday, December 16th, Jack Anders sold 3,104 shares of Revolution Medicines stock. The stock was sold at an average price of $77.09, for a total transaction of $239,287.36.

Revolution Medicines Stock Up 10.5%

Shares of RVMD traded up $11.25 on Friday, hitting $118.64. The company’s stock had a trading volume of 20,660,272 shares, compared to its average volume of 9,321,702. The firm has a market capitalization of $22.94 billion, a price-to-earnings ratio of -22.95 and a beta of 0.99. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $121.62. The firm’s fifty day moving average price is $75.17 and its 200-day moving average price is $53.43. The company has a quick ratio of 8.05, a current ratio of 8.05 and a debt-to-equity ratio of 0.16.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, November 5th. The company reported ($1.61) EPS for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same quarter in the previous year, the company posted ($0.94) earnings per share. On average, equities research analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Hedge Funds Weigh In On Revolution Medicines

A number of hedge funds have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC raised its stake in shares of Revolution Medicines by 2.1% in the third quarter. Farallon Capital Management LLC now owns 14,625,692 shares of the company’s stock worth $683,020,000 after purchasing an additional 300,000 shares during the last quarter. Baker BROS. Advisors LP raised its position in Revolution Medicines by 1.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 9,455,357 shares of the company’s stock valued at $441,565,000 after buying an additional 90,385 shares during the last quarter. Nextech Invest Ltd. lifted its stake in Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after acquiring an additional 1,304,347 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its stake in Revolution Medicines by 2.1% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 6,223,291 shares of the company’s stock valued at $290,628,000 after acquiring an additional 130,000 shares in the last quarter. Finally, Bellevue Group AG boosted its holdings in Revolution Medicines by 21.7% during the 3rd quarter. Bellevue Group AG now owns 5,573,838 shares of the company’s stock worth $260,298,000 after acquiring an additional 994,538 shares during the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Reports that Merck is in talks to acquire Revolution Medicines for roughly $30–32 billion, a direct M&A bid narrative that can justify a sizable takeover premium and is the primary driver of today’s rally. Merck in talks (WSJ)
• Positive Sentiment: Takeover buzz broadened as media reported additional suitors and renewed buyout interest (markets often bid target stocks higher on competing-acquirer speculation). Takeover buzz, another suitor emerges (Barron’s)
• Positive Sentiment: FDA granted Breakthrough Therapy Designation to zoldonrasib for KRAS G12D-mutant NSCLC — a substantive clinical/regulatory win that strengthens RVMD’s strategic value to acquirers and supports a higher acquisition valuation. Breakthrough Therapy Designation (GlobeNewswire)
• Positive Sentiment: Unusual options activity — a large spike in call buying — indicates aggressive bullish/speculative positioning by traders ahead of or on takeover rumors, amplifying short-term upside momentum. (market reports)
• Neutral Sentiment: The stock experienced a temporary LULD (limit up/limit down) pause during trading, a procedural volatility-control measure that often accompanies sudden price moves but does not change fundamentals.
• Negative Sentiment: Earlier takeover reports referenced AbbVie interest but AbbVie publicly denied talks, which previously triggered volatility and a pullback — a reminder that rumor-driven moves can reverse if potential bidders decline to engage. AbbVie denies talks (Barron’s)
• Negative Sentiment: Revolution remains a loss-making biotech (recent quarterly EPS missed estimates), so absent a takeover premium the stock’s valuation relies on successful late-stage clinical outcomes and eventual commercialization. (company filings/earnings)

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on RVMD shares. National Bankshares set a $80.00 price objective on shares of Revolution Medicines in a research report on Friday, October 17th. Raymond James Financial boosted their target price on shares of Revolution Medicines from $72.00 to $76.00 and gave the company a “strong-buy” rating in a research report on Friday, October 17th. Wells Fargo & Company lifted their target price on Revolution Medicines from $67.00 to $70.00 and gave the company an “overweight” rating in a research report on Thursday, September 11th. The Goldman Sachs Group upped their price target on shares of Revolution Medicines from $65.00 to $73.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Revolution Medicines from $71.00 to $82.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Four analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Revolution Medicines currently has a consensus rating of “Buy” and a consensus target price of $78.94.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.